Embryo Selection by Time Lapse Monitoring for Single Embryo Transfer ("SET")

January 16, 2018 updated by: Kaali Institute IVF Center

Time Lapse Embryo Monitoring Versus Standard Embryo Monitoring for Selection for Single Blastocyst Transfer

A multiple pregnancy is an undesired outcome of assisted reproduction. Current embryo selection technologies are inefficient in identifying the embryo with the highest implantation potential. Time lapse (TL) embryo monitoring provides additional information about embryo development and therefore may aid embryo selection. The investigators aim is to study whether TL monitoring is superior to traditional embryo observation when a single blastocyst is selected for transfer (ET).

Study Overview

Detailed Description

Prospective RCT comparing two embryo selection methods (TL algorithm vs standard morphology based) for SET. Infertile couples scheduled to undergo IVF or intracytoplasmic sperm injection (ICSI) and met the inclusion-exclusion criteria were enrolled. Randomization to Groups 1 or 2 was performed prior to the start of stimulation. Randomization was carried out in blocks of two, by selecting TL or control assignments from closed, opaque envelopes. Patients were blinded to allocation. Standard luteal long (Suprefact, Sanofi Aventis) and flexible gonadotropin-releasing hormone (GnRH) antagonist (Cetrotide, Merck Serono) protocols and recombinant FSH(Gonal-f, Merck Serono) were used for stimulation. Embryos were placed into individual wells of a 9-well Primo Vision culture dish (Vitrolife AB, Sweden) on day 1 of culture, after checking for fertilization. Out of incubator handling was same in the groups;: day 1: fertilization check; day 3: culture medium change; day 5: transfer. On days 3 and 5, the embryos were morphologically assessed under an inverted microscope. Embryos in TL group were imaged at 10-minute intervals. The Primo Vision software was used for the analysis of TL images. The first appearance of the 2, 3, 4 and 5 cell stages (t2, t3, t4 and t5, respectively) were annotated. Timing of the kinetic events was calculated from the time of the fertilization (t0). (for TL parameter definitions see supplement) There were no adjustments of the kinetic events depending on the method of fertilization. Blastocyst morphology was assessed using the Gardner score. Fragmentation was assessed when it reached the highest grade in the sequence of the TL images. Cytoplasmic abnormalities (vacuoles) were also recorded. The TL reference ranges were defined and fixed before the start of the recruitment, Embryos in the control group were selected based on actual morphology. The primary end point was pregnancy rate (PR; rise in β human chorionic gonadotropin [hCG]) per patient based on intention to treat. Further endpoints were ongoing pregnancy rate (OPR; pregnancy that progresses beyond 12 weeks gestation), pregnancy loss (loss of pregnancy after an initial rise in βhCG up to 12 weeks gestation), live birth rate (LBR), gestational age (GA) at delivery and birth weight of the offspring.

When calculating sample size we assumed a 13% increase in pregnancy rate from an expected 42% to 55%. We planned to run the study with 1:1 ratio between the groups and do one interim monitoring with 0.1 information fraction. Using two-sided test and Pocock boundaries for estimation, 282 patients in each group was calculated (power of 80%, p of 5%). Assuming a 10% dropout rate we needed to enroll 620 patients.

Based on the results of the interim monitoring (61 cases in two arms) the pregnancy rate in the TL group was 15% higher than in controls (58.3% vs. 44.0%). Assuming 58% pregnancy rate in the TL group and 44% in controls, a sample size of 210 per group, was needed to achieve a power of 80%, at a significance level of 5%. Assuming 10% dropout rate a total sample of size of 462 patients were needed.

The groups were compared based on maximum likelihood estimation principles. We hypothesized and then showed that the patients in the treatment arms were similar at baseline, on average, with respect to variables that might influence outcome. Chi-square tests, likelihood-ratio tests and exact tests were used for the analysis of categorical variables. Continuous variables were compared using independent group t-test and. analysis of variance. Normality and homogeneity of variances were examined.

At the interim analysis of the trial the primary endpoint (pregnancy rate) between TL and control group was compared with Fisher's exact test. After closing the trial the primary endpoint (pregnancy rate) among the groups was compared with Fisher's exact test. Bonferroni correction was used for the p-value at the end of the trial. All other p-values were considered exploratory in nature. During the analyses the extent and distribution of missing data were also examined. No imputations were made for missing data.

Study Type

Interventional

Enrollment (Actual)

161

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Budapest, Hungary, 1125
        • Kaali Institute IVF Center
      • Budapest, Hungary, 1205
        • Forgacs Intezet

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 36 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Age < 36 yrs
  • baseline FSH <10 IU/l
  • regular 25-35 day cycles
  • less than 2 previous failed IVF cycles
  • intact uterus
  • an indication for IVF
  • BMI <18- <30 kg/m2
  • acceptance of single embryo transfer

Exclusion Criteria:

  • PCOS
  • Sperm obtained by surgical extraction
  • chromosome abnormality
  • Presence of hydrosalpinx
  • stage III/IV endometriosis
  • Less than 3 good quality day 3 embryos
  • only one good quality day 5 embryos
  • lack of consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: time-lapse morphokinetic evaluation
Embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse: upon fertilization embryos in a petri dish that allows individual assessment (Primo Vision Dish) are placed onto an automated time-lapse equipment in an incubator. The time-lapse equipment performs imaging in 10 minutes intervals. The software is presenting the up-to-date images and allows the operator to assess the "time-lapse" movie of the developmental history of the embryos to perform annotations and apply evaluation/selection algorithm. This morpho-kinetic TL algorithm (made up of standard moprhology as seen on time lapse and kinetci scores) is used for embryo selection, which actually describes the intervention.
embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
Other Names:
  • time-lapse morphokintic score
No Intervention: standard embryo monitoring
Upon fertilization embryos are observed once on days 1-3-5 by the embryologist to check for development. The single embryo for transfer is selected based on actual morphology as seen under light microscope.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pregnancy Rate
Time Frame: 12-14 days after transfer
rise in beta HCG 12-14 days after transfer
12-14 days after transfer

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Live Birth
Time Frame: delivery after 24 weeks
live birth after 24 weeks gestation
delivery after 24 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time Lapse Score
Time Frame: the time lapse score is assessed on the day of embryo transfer (day 5 after the egg retrieval)
a score based on 8 observations by time lapse monitoring
the time lapse score is assessed on the day of embryo transfer (day 5 after the egg retrieval)
Perinatal Outcome
Time Frame: perinatal outcome assessed after delivery
gestational age at delivery, birth weight,
perinatal outcome assessed after delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Peter Kovacs, MD, Kaali Inst. IVF Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Actual)

April 1, 2015

Study Completion (Actual)

April 1, 2015

Study Registration Dates

First Submitted

September 21, 2012

First Submitted That Met QC Criteria

September 25, 2012

First Posted (Estimate)

September 27, 2012

Study Record Updates

Last Update Posted (Actual)

February 13, 2018

Last Update Submitted That Met QC Criteria

January 16, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Clinical Pregnancy After Single Embryo Transfer

Clinical Trials on time-lapse morphokinetic evaluation

3
Subscribe